Literature DB >> 8348391

Calcium antagonists in heart transplant recipients: effects on cardiac and renal function and cyclosporine pharmacokinetics.

L Legault1, R I Ogilvie, C J Cardella, F H Leenen.   

Abstract

OBJECTIVE: Cyclosporine increases transmembrane calcium flux in mesangial and vascular smooth muscle cells, which may explain cyclosporine-induced decreases in renal bloodflow and glomerular filtration rate. Calcium antagonists, thus, may play a role in the prevention/reversal of cyclosporine nephrotoxicity.
DESIGN: In a single-blind, randomized, cross-over study the authors evaluated the effects of a one-week treatment with nifedipine 20 mg bid, diltiazem 120 mg bid or placebo on cardiac and renal functions of six stable heart transplant recipients treated chronically with cyclosporine.
RESULTS: Both calcium antagonists lowered blood pressure compared with placebo, but only nifedipine increased cardiac output and, therefore, decreased total peripheral resistance significantly more than diltiazem. Nifedipine induced a significant increase in effective renal plasma flow and an insignificant increase in glomerular filtration rate, whereas diltiazem caused a reduction in these parameters. Cyclosporine pharmacokinetics were not affected by either calcium antagonist to a clinically significant extent.
CONCLUSIONS: Nifedipine and diltiazem exert distinctly different cardiac and renal hemodynamic effects in cardiac transplants, which may have clinical consequences.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8348391

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  1 in total

1.  Prediction of systemic exposure to cyclosporine in Japanese pediatric patients.

Authors:  Toshiyuki Sakaeda; Kazumoto Iijima; Kandai Nozu; Tsutomu Nakamura; Yuka Moriya; Mika Nishikawa; Atsushi Wada; Noboru Okamura; Masafumi Matsuo; Katsuhiko Okumura
Journal:  J Hum Genet       Date:  2006-09-14       Impact factor: 3.172

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.